The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Affecting approximately 4,500 people annually in the U.S., AL amyloidosis can be associated with blood cancers, particularly multiple myeloma as well as lymphomas or chronic lymphocytic leukemia.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating advanced solid tumours and multiple myeloma. The dosing was conducted at The ...

Affecting approximately 4,500 people annually in the U.S., AL amyloidosis can be associated with blood cancers, particularly ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

The Jefferson County Senior Services Division is hosting The MMRF Multiple Myeloma Community Connect event on Thursday, Nov.

KRd56 and KRd27 regimens showed no significant difference in ORR or PFS for relapsed/refractory multiple myeloma patients. Both regimens had similar safety profiles, with common side effects like ...